Sandoz Seeks U.S. High Court Review On Law Over Biologics, Patents

(March 17, 2016, 2:12 PM EDT) -- WASHINGTON, D.C. — An appellate court erred in finding that biosimilar makers must wait until their products receive U.S. Food and Drug Administration approval before providing 180-day advance notice of sales, Sandoz Inc. tells the U.S. Supreme Court in a Feb. 16 petition, asking that it review a ruling with regard to the Biologics Price Competition and Innovation Act (Sandoz, Inc. v. Amgen, Inc. and Amgen Manufacturing, Ltd., No. 15-1039, U.S. Sup.).

(Petition for writ of certiorari available. Document #78-160321-004B.)

Competing motions for en banc rehearing...
To view the full article, register now.